The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence.
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
Works matching IS 09546820 AND DT 2006 AND VI 259 AND IP 5
Results: 14
1
2
Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 481, doi. 10.1111/j.1365-2796.2006.01644.x
- By:
- Publication type:
- Article
3
The rationale for using apoA-I as a clinical marker of cardiovascular risk.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 447, doi. 10.1111/j.1365-2796.2006.01647.x
- By:
- Publication type:
- Article
4
Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease [corrected] [published erratum appears in J INTERN MED 2006 Aug;260(2):186].
- Published in:
- 2006
- By:
- Publication type:
- Journal Article
5
Combined hormone replacement therapy improves lipids but may increase leucocytes.
- Published in:
- 2006
- By:
- Publication type:
- Letter
6
Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 437, doi. 10.1111/j.1365-2796.2006.01648.x
- By:
- Publication type:
- Article
7
Respiratory symptoms as predictors of all-cause mortality in an urban community: a 30-year follow-up.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 520, doi. 10.1111/j.1365-2796.2006.01631.x
- By:
- Publication type:
- Article
8
Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 530, doi. 10.1111/j.1365-2796.2006.01632.x
- By:
- Publication type:
- Article
9
The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 493, doi. 10.1111/j.1365-2796.2006.01643.x
- By:
- Publication type:
- Article
10
Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 434, doi. 10.1111/j.1365-2796.2006.01650.x
- By:
- Publication type:
- Article
11
Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 473, doi. 10.1111/j.1365-2796.2006.01645.x
- By:
- Publication type:
- Article
12
Apolipoproteins AI and B as therapeutic targets.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 462, doi. 10.1111/j.1365-2796.2006.01646.x
- By:
- Publication type:
- Article
13
ApoB and apoA-I – new markers of cardiovascular risk.
- Published in:
- 2006
- Publication type:
- Table of Contents
14
Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
- Published in:
- Journal of Internal Medicine, 2006, v. 259, n. 5, p. 455, doi. 10.1111/j.1365-2796.2006.01649.x
- By:
- Publication type:
- Article